Login to Your Account

Amal adds $9.5M in first series B close for colorectal cancer vaccine

By Nuala Moran
Staff Writer

Tuesday, September 5, 2017

LONDON – Amal Therapeutics SA announced the first closing of its series B funding, raising €8 million (US$9.5 million) of a proposed €20 million round to progress its lead cancer vaccine, ATP-128, into the clinic.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription